IX at IPVS 2026: Listening to Global Voices, Partnering to Advance HPV Prevention
ATHENS, Greece, Oct. 27, 2026 /PRNewswire/ -- Xiamen Innovax Biotech Co., Ltd. (IX) participated in the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), held in Athens, Greece, from October 22 to 25, joining global experts and partners to exchange scientific insights and explore collaborative approaches to HPV prevention and cervical cancer elimination. Under the theme...
Natus Celebrates Grand Opening of Suzhou Facility – Advancing Innovation in China, for China
Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China SUZHOU, China, Oct. 27, 2026 /PRNewswire/ -- Natus Medical Incorporated, the world's largest pure-play neurodiagnostic company, today celebrated the grand opening of its development and manufacturing facility in Suzhou. “Our mission is to improve outcomes and...
Asia-Pacific’s First Whole-Body Clinical 5T MRI System Installed in Vietnam, Advancing a New Regional High-Field MRI Center of Excellence
HANOI, Vietnam, Oct. 27, 2026 /PRNewswire/ -- On October 26, 2026, United Imaging Healthcare's uMR Jupiter 5T MRI system was officially introduced at Hanoi Medical University Hospital (HMUH), marking the arrival of the first whole-body clinical 5T MRI in the Asia-Pacific region (outside China). The launch ceremony was attended by H.E. He Wei, Ambassador of the People's Republic of China...
MEPSGEN Launches NanoCalibur® Mini for Small-Volume Nanoparticle Formulation
Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., a global innovator in drug delivery system platforms, today announced the launch of NanoCalibur® Mini, an automated...
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 generative AI platform. Among response-evaluable participants with mesothelioma, the results showed a 40.0% objective response rate (ORR) at 130 mg once daily...
TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading programs in this class globally - First patient dosing marks a key milestone for TJ Biopharma's next-generation innovation pipeline HANGZHOU, China, Oct. 26, 2026 /PRNewswire/ -- TJ Biopharma ("TJ Bio" or "the Company"), a fully...
Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology
CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis of the Phase III OptiTROP-Breast01 study for sacituzumab tirumotecan (sac-TMT,...
CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue
HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is metabolised very differently in the body. Research into fructose metabolism and its regulation of metabolism in the human body has in recent years become a frontier topic in the life sciences and medicine....
WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers’ Products and CRDMO Model
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 ("Reporting Period"). The Company further raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the...
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that a New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) has been accepted for review...
